ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 51 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $58,742 | +56.4% | 46,072 | -60.0% | 0.00% | – |
| Q2 2023 | $37,559 | -24.2% | 115,210 | 0.0% | 0.00% | – |
| Q1 2023 | $49,540 | -19.9% | 115,210 | -1.3% | 0.00% | – |
| Q4 2022 | $61,881 | -27.2% | 116,757 | 0.0% | 0.00% | – |
| Q3 2022 | $85,000 | -35.1% | 116,757 | +1.5% | 0.00% | – |
| Q2 2022 | $131,000 | -44.5% | 114,982 | -0.2% | 0.00% | – |
| Q1 2022 | $236,000 | -32.0% | 115,209 | -4.4% | 0.00% | – |
| Q4 2021 | $347,000 | -40.6% | 120,469 | -12.5% | 0.00% | – |
| Q3 2021 | $584,000 | -8.6% | 137,704 | +14.0% | 0.00% | – |
| Q2 2021 | $639,000 | +38.0% | 120,744 | +21.1% | 0.00% | – |
| Q1 2021 | $463,000 | +12.4% | 99,684 | -20.1% | 0.00% | – |
| Q4 2020 | $412,000 | -10.4% | 124,736 | -10.2% | 0.00% | – |
| Q3 2020 | $460,000 | +2.0% | 138,859 | +3.6% | 0.00% | – |
| Q2 2020 | $451,000 | -64.2% | 133,974 | -59.3% | 0.00% | – |
| Q1 2020 | $1,261,000 | -33.9% | 329,381 | +4.2% | 0.00% | – |
| Q4 2019 | $1,909,000 | -19.9% | 316,074 | +0.3% | 0.00% | -100.0% |
| Q3 2019 | $2,382,000 | +76.7% | 315,075 | +216.7% | 0.00% | – |
| Q2 2019 | $1,348,000 | +241.3% | 99,498 | +36.3% | 0.00% | – |
| Q1 2019 | $395,000 | +53.1% | 72,996 | -16.1% | 0.00% | – |
| Q4 2018 | $258,000 | -66.8% | 86,955 | -8.7% | 0.00% | – |
| Q3 2018 | $776,000 | +26.8% | 95,202 | +51.7% | 0.00% | – |
| Q2 2018 | $612,000 | -57.9% | 62,741 | -62.5% | 0.00% | – |
| Q1 2018 | $1,455,000 | -18.5% | 167,342 | +17.3% | 0.00% | – |
| Q4 2017 | $1,786,000 | +57.2% | 142,679 | +5.0% | 0.00% | – |
| Q3 2017 | $1,136,000 | -50.7% | 135,892 | +0.0% | 0.00% | -100.0% |
| Q2 2017 | $2,306,000 | +339.2% | 135,876 | +420.5% | 0.00% | – |
| Q1 2017 | $525,000 | +38.9% | 26,106 | +7.7% | 0.00% | – |
| Q4 2016 | $378,000 | +27.3% | 24,247 | +6.4% | 0.00% | – |
| Q3 2016 | $297,000 | -7.5% | 22,779 | -32.8% | 0.00% | – |
| Q1 2016 | $321,000 | -6.1% | 33,919 | 0.0% | 0.00% | – |
| Q4 2015 | $342,000 | – | 33,919 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |